Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
This triple mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 agonist)
Another $43 million from other investors followed in the next few years
This model emphasizes convenience and consistent clinical protocols
433 This is especially valuable for differentiating pseudoprogression from true progression during immunotherapy, potentially prompting revisions to existing RECIST criteria
US$ 29.08
US$ 21.46
US$ 22.75
US$ 20.05
US$ 21.63
US$ 24.79
US$ 22.70
US$ 26.70
US$ 26.11
